May 12, 2026
A New Jersey appellate panel on Tuesday pushed back on an investor's insistence that his complaint over Bristol-Myers Squibb's $74 billion acquisition of Celgene satisfied pleading standards for securities lawsuits, echoing a trial court judge's concern that claims of disclosure requirement shortfalls sounded more in fraud than negligence.
September 23, 2022
A New Jersey federal judge has sent back to state court class claims alleging Bristol-Myers Squibb Co. misled investors with respect to its $74 billion acquisition of Celgene Corp., dealing another blow to the pharmaceutical giant after it recently lost its bid to keep a similar case in New York federal court.